TY - JOUR
T1 - Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the Netherlands
AU - Medical Microbiological Laboratories and the Public Health Services
AU - Woestenberg, Petra J
AU - King, Audrey J
AU - Van Benthem, Birgit H B
AU - Leussink, Suzan
AU - Van der Sande, Marianne A B
AU - Hoebe, Christian J P A
AU - Bogaards, Johannes A
N1 - BOAC; FTX;
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].
PY - 2020
Y1 - 2020
N2 - Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.
AB - Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.
U2 - 10.1093/infdis/jiz187
DO - 10.1093/infdis/jiz187
M3 - A1: Web of Science-article
C2 - 31100134
SN - 0022-1899
VL - 221
SP - 1280
EP - 1285
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 8
ER -